Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2914445> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q2914445 subject Q8421769.
- Q2914445 abstract "Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin. CERAs have an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs.Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. FDA in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis. (Patent disputes between Amgen, which owns several patents relating to recombinant EPO variants, and Roche are blocking distribution of Mircera in the U.S. This issue appears to have been resolved since Fresenius Medical dialysis clinics in the US are now administering this drug.)Methoxy polyethylene glycol-epoetin beta previously was approved by the European Commission in August 2007, and was made available in Europe at the start of 2008.In terms of its structure, Mircera is similar to the previous synthetic EPO drugs, except that it is connected to a chemical called polyethylene glycol (PEG), which makes it last longer in the body. According to Roche, the product has the longest half-life of all FDA-approved erythropoiesis-stimulating agents (ESAs): up to 6 times longer than darbepoetin alfa and up to 20 times longer than epoetin. CERAs thus promise both lower dosing—significant owing to the high inherent cost of manufacturing recombinant protein drugs—and less frequent injections for patients. ESAs are administered via subcutaneous injections, often in doctor's offices for patients who lack the skill or dexterity to inject themselves, so the once- or twice-monthly dosing regimen for CERAs promises fewer costly, inconvenient office visits for patients requiring constant hemoglobin level maintenance for chronic kidney disease.In clinical trials, CERA dosed every 3 to 4 weeks demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials.".
- Q2914445 wikiPageWikiLink Q110631.
- Q2914445 wikiPageWikiLink Q1158.
- Q2914445 wikiPageWikiLink Q1354195.
- Q2914445 wikiPageWikiLink Q1363798.
- Q2914445 wikiPageWikiLink Q14852026.
- Q2914445 wikiPageWikiLink Q166376.
- Q2914445 wikiPageWikiLink Q202301.
- Q2914445 wikiPageWikiLink Q212646.
- Q2914445 wikiPageWikiLink Q221530.
- Q2914445 wikiPageWikiLink Q2429962.
- Q2914445 wikiPageWikiLink Q315111.
- Q2914445 wikiPageWikiLink Q318378.
- Q2914445 wikiPageWikiLink Q33861.
- Q2914445 wikiPageWikiLink Q358263.
- Q2914445 wikiPageWikiLink Q379690.
- Q2914445 wikiPageWikiLink Q40970.
- Q2914445 wikiPageWikiLink Q410083.
- Q2914445 wikiPageWikiLink Q4219822.
- Q2914445 wikiPageWikiLink Q43041.
- Q2914445 wikiPageWikiLink Q447087.
- Q2914445 wikiPageWikiLink Q48663.
- Q2914445 wikiPageWikiLink Q5384501.
- Q2914445 wikiPageWikiLink Q5445.
- Q2914445 wikiPageWikiLink Q60857.
- Q2914445 wikiPageWikiLink Q6823893.
- Q2914445 wikiPageWikiLink Q736715.
- Q2914445 wikiPageWikiLink Q79913.
- Q2914445 wikiPageWikiLink Q8421769.
- Q2914445 wikiPageWikiLink Q8567.
- Q2914445 wikiPageWikiLink Q8880.
- Q2914445 comment "Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin. CERAs have an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs.Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S.".
- Q2914445 label "Continuous erythropoietin receptor activator".